olfactory receptor family 1 subfamily M member 1Genealiases: OR19-5 · OR19-6
Q-omics provides the consensus-scored OR1M1 profile across patient tissues and cancer cell-line models. OR1M1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OR1M1 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, OR1M1 RNA expression shows 6,496 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, LUSC, and STAD as cancer lineages where OR1M1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR1M1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR1M1 survival associations across molecular data types. OR1M1 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR1M1 RNA expression–survival associations across cancer types. High OR1M1 expression shows unfavorable associations in ACC, THCA, READ, LUAD and SKCM, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OR1M1 RNA expression.
This table summarizes OR1M1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR1M1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR1M1 shows lower tumor expression in LUSC and STAD and higher tumor expression in KIRC and LUAD. The LUSC box plot shows higher OR1M1 RNA expression in normal versus tumor tissue (log2 FC = −0.018, t-test p = .023).
This table shows molecular features associated with OR1M1 in patient tissues and cancer cell lines. In patient samples, OR1M1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR1M1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
